$4.72
-3.7%Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Chief Medical Officer
Chief Operating Officer
Director & Co-Founder
Director & Co-Founder
Director & Co-Founder
Director & Co-Founder
President, Chief Executive Officer & Director
Principal Financial Officer & Principal Accounting Officer
During the last 12 months, insiders have purchased $7.35M and sold $13K worth of KLRS shares, resulting in $7.34M of net buying activity.
244.3K
1.18M
1.9K
12.87K
+1.2M
+$1.17M
479.8K
5.00M
0
0.00
+5.0M
+$5.00M
235.0K
1.17M
0
0.00
+1.2M
+$1.17M
0
0.00
0
0.00
+0
+$0
Akkaraju Srinivas
Director, 10 Percent Owner:
$6.18M
Gall Matthew
Officer: Chief Financial Officer
$1.17M
Hagen Brett R
Officer: Chief Accounting Officer
$13K
Strong bullish signal with $7.34M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
2 insider buyers vs. 1 sellers. More insiders buying than selling indicates positive sentiment.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
KLRS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 03, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | July 01, 2025 | August 12, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | December 06, 2024 | January 09, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | March 31, 2023 | May 11, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 06, 2022 | May 17, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 12, 2021 | May 25, 2021 | 2021 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.